DarioHealth (DRIO) Q3 2026 earnings summary

Executive summary

• Q3 revenue rose 6.1% YoY to $5.311M; operating expenses fell 10% and operating loss improved 15%.

• Commercial momentum included new health-plan agreements, account expansions, Dario Women and Dario Sleep launches, and broader DarioIQ deployment.

Financial highlights

• Q3 revenue was $5.311M versus $5.007M; 9M revenue was $16.071M versus $17.128M, reflecting non-recurring prior-year pharmaceutical revenue.

• Q3 operating expenses were $11.2M; operating loss was $8.045M versus $9.484M, and net loss was $8.849M versus $10.5M.

• 9M operating expenses fell 17% to $31.4M; operating loss improved 22% to $21.833M and net loss improved to $25.022M.

• Adjusted Q3 operating loss was $5.316M versus $5.987M; 9M adjusted loss was $15.991M versus $18.162M.

• Q3 gross profit was $3.145M; 9M gross profit was $9.538M, including a $448K tariff-refund benefit in cost of revenues.

Outlook and guidance

• Contracted and late-stage ARR totaled $13.1M, with more than 80% tied to multi-condition opportunities; management expects gradual conversion from late 2026, mainly in 2027 and continuing into 2028.

• Management expects revenue acceleration in 2027, with analyst consensus aligned to its expectations; it sees a path to break-even in 2028.

• A Fortune 50 employer selected the integrated cardiometabolic platform for 100,000+ eligible employees, with commercial launch expected in H1 2027.

• Expanded provider-backed women’s health and sleep offerings were expected to begin contributing in Q4 2026; the New Jersey plan and expanded Dario Women offering are expected to contribute in 2027.

• Cash and short-term deposits were expected to support operations for at least 12 months from issuance of the interim statements; longer-term funding needs remain uncertain.